» Articles » PMID: 3621134

The Measurement of Performance in Childhood Cancer Patients

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1987 Oct 1
PMID 3621134
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

The performance status of the child with cancer is an important outcome consideration in pediatric oncology research and practice. However, no single measure for children has been available. This is a report of the development and standardization of such a scale. The play-performance scale for children is a parent-rated instrument which records usual play activity as the index of performance. Performance status ratings were obtained on three groups of children: patients (n = 98), patients' siblings (n = 29), and an independent sample of hospital employees' children (n = 40). Children with all types and stages of childhood malignant neoplasms were represented. Test results established the parent as a competent, reliable rater and demonstrated the validity of the scale. Interrater reliability was examined using correlational statistics and percentage agreement. Agreement between parents was good, and there were no systematic rater biases. In addition, parents' ratings significantly discriminated differences in levels of functioning (mean score, patients 75.4 versus siblings 97.4). Correlational and analysis of variance (ANOVA) procedures demonstrated that the play-performance scale was significantly related to the global performance measures of experienced clinicians and was sensitive to change. Inpatients received a mean score of 42.3, outpatients 90.7, and normals 98.2. These findings indicate that the scale is both feasible and effective. It is concise, can be administered repeatedly even to extremely ill patients, and uses parents as observer reporters. The play-performance scale for children provides quantifiable, reproducible, and meaningful data, which is necessary for effective monitoring and management of the child with cancer.

Citing Articles

The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.

Mora J, Chan G, Morgenstern D, Amoroso L, Nysom K, Faber J Nat Commun. 2025; 16(1):1636.

PMID: 39952926 PMC: 11828896. DOI: 10.1038/s41467-025-56619-x.


MMFP-Tableau: enabling precision mitochondrial medicine through integration, visualization, and analytics of clinical and research health system electronic data.

George-Sankoh I, MacMullen L, Chinwalla A, Taylor D, Ganetzky R, Stanley K JAMIA Open. 2024; 7(4):ooae134.

PMID: 39559492 PMC: 11570990. DOI: 10.1093/jamiaopen/ooae134.


Impact of Functional Status at the Time of Transplant on Short-Term Pediatric Lung Transplant Outcomes in the USA.

Koh W, Zang H, Ollberding N, Perry T, Morales D, Hayes Jr D Lung. 2024; 202(6):775-783.

PMID: 39325187 DOI: 10.1007/s00408-024-00752-9.


Functional performance assessment scale for children and adolescents with cancer: cross-cultural study.

Carmo S, Oliveira I, Cardoso S, Gois J, Costa C, Noronha R Rev Bras Enferm. 2024; 77(2):e20230331.

PMID: 38896710 PMC: 11178304. DOI: 10.1590/0034-7167-2023-0331.


Pulmonary hypertension in the intensive care unit after pediatric allogeneic hematopoietic stem cell transplant: incidence, risk factors, and outcomes.

Smith M, Cheng G, Phelan R, Brazauskas R, Strom J, Ahn K Front Oncol. 2024; 14:1415984.

PMID: 38868534 PMC: 11167102. DOI: 10.3389/fonc.2024.1415984.